On Monday, AtriCure received an upgrade to its Relative Strength (RS) Rating, from 66 to 72.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary rating identifies price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating of at least 80 in the early stages of their moves. See if AtriCure can continue to show renewed price strength and hit that benchmark.
AtriCure is building a cup with handle with a 38.33 entry. See if the stock can break out in volume at least 40% higher than normal.
The company reported 0% earnings growth in the latest quarterly report. Revenue gains came in at 17%. The next quarterly numbers are expected on or around Oct. 29.
The company earns the No. 7 rank among its peers in the Medical-Systems/Equipment industry group. iRadimed, IDEXX Laboratories and Brainsway ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
